Daniel Getts

Metabolon, Inc. operates as a health technology company. It offers precision medicine, clinical diagnostic, and metabolomics services. The firm serves to the pharmaceutical, biotechnology, consumer product industries. The company was founded in 2000 and is headquartered in Morrisville, NC.

Part of Advanced Biological Laboratories SA, TherapyEdge, Inc. provides a database for HIV patient's clinical records. The company is based in Durham, NC. TherapyEdge was acquired by Advanced Biological Laboratories SA on February 14, 2005.

Eight Roads Capital Advisors (Hong Kong) Ltd(Eight Roads Capital) is a venture capital firm founded in 1900. Headquartered in Hong Kong.

GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA.

Novartis Venture Fund provides early stage venture capital to companies in Europe, North America and Asia. The fund's focus is on the development of novel therapeutics and platforms, therefore it focuses on such sectors as Biotechnology and Biopharma. The fund makes seed and early stage investments ranging up to USD 30 million per company over its life. The fund makes follow-on and co-investments.

Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA.

eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA.

Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA.

Forerunner Medical Equipment Technology Shanghai Co. Ltd. engages in the manufacture, sale of pharmaceutical products and medical equipment. The company was founded by Jie Qin in 2009 and is headquartered in Shanghai, China.

Medeor Therapeutics, Inc. engages in medical industry. It provides services which are dedicated to the discovery, development, and commercialization of transformative and personalized cellular therapeutics. The company was founded by Samuel Strober, Edgar Engleman, Robert Lowsky, and Chih Ping in 2012 and is headquartered in South San Francisco, CA.

Nimbus Apollo, Inc. provides drug discovery research services. The company is headquartered in Cambridge, MA.

Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom.

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

LifeMine Therapeutics, Inc. develops drugs from fungi which aims to cure untreatable and significant chronic diseases. The company was founded by Gregory L. Verdine, WeiQing Zhou, Richard D. Klausner and Hingge Hsu and is headquartered in Cambridge, MA.

Part of Pfizer Inc., Pfizer Ventures LLC is a venture capital arm that invests in areas of current or future strategic interest to Pfizer. The company is based in New York, NY. Pfizer Ventures seeks to identify and invest in emerging companies that are developing breakthroughs and technologies that have the potential to enhance Pfizer's pipeline and shape the future of the industry.

Jnana Therapeutics, Inc. provides drug development services. The firm focuses on immunometabolism changing the metabolic pathways in immune cells to affect function; lysosomal function and mucosal defense. The company was founded by Stuart L. Schreiber, Ramnik Xavier, Joanne Kotz and Joel C. Barrish and is headquartered in Boston, MA.

Dewpoint Therapeutics, Inc. develops drugs. The company is headquartered in Boston, MA.

Part of GSK Plc, SmithKline Beecham Pharmaceuticals Co. is a company that manufactures drugs and vaccines. The company is based in Philadelphia, PA.

Creacion Ventures Management LLC (Creacion Ventures) is a venture capital firm founded in 2020. The firm is headquartered in Boston, Massachusetts.

Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020.

Frontera Therapeutics, Inc. is an American biotechnology company that focuses on the research and development of innovative drugs for various diseases such as eye, blood, genetic metabolism, neuromuscular, and others. The company is based in Shanghai, China, and has subsidiaries in Suzhou, China. Frontera Therapeutics specializes in producing high-quality and affordable recombinant adeno-associated virus (rAAV) carrier gene therapy products to meet the treatment needs of hereditary and chronic diseases. The company was founded in September 2019 by Hongyuan Capital and Obo Capital Investment, and it brings together professionals with rich experience in drug research and development, clinical research, registration, and production management.